AbbVie announced patent license agreements with Momenta over its proposed biosimilar adalimumab product.
Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie’s intellectual property relating to Humira in the United States and in various other countries around the world in which AbbVie has intellectual property:
Momenta will pay royalties to AbbVie for licensing its Humira patents and acknowledges the validity of the licensed patents. AbbVie will make no payments to Momenta. The precise terms are confidential between the parties.
AbbVie’s previously announced U.S. dates for patent licenses are: